Epithalon: a four-amino-acid peptide and a single-lineage evidence base

Four amino acids, a pulse schedule of ten days twice a year, and a set of claims about telomerase and lifespan that rest almost entirely on the work of one research lineage. That last fact is the most useful thing to know before reading anything else about it.

Where it comes from

Epithalon is a synthetic tetrapeptide — alanine, glutamate, aspartate, glycine — developed as the synthetic counterpart of epithalamin, a peptide preparation extracted from pineal tissue. Both belong to a family of short peptide preparations developed in Russian gerontology research from the 1970s onward, and the app groups them under that programme's name.

Animal-only or theoretical The claims associated with it are unusually specific: activation of telomerase and consequent telomere elongation in cell culture, normalisation of melatonin rhythm, antioxidant effects, reduced tumour incidence in animal models, and increased lifespan in rodents. The reported experiments exist and are published. What is thin is replication outside the group that produced them, which is a different criticism from saying the work is wrong and a more important one.

The human evidence most often cited is a long-running cohort followed over several years with reported reductions in mortality. The design of that work — its allocation, its controls and its outcome ascertainment — does not meet the standard a contemporary trial would be held to, and the effect sizes reported are large enough that the design question is not a technicality.

Why telomerase activation is not the reassuring claim it sounds like

Animal-only or theoretical Telomere shortening is a real feature of cell ageing and telomerase is the enzyme that counteracts it, so "activates telomerase" reads as straightforwardly good. The biology is less tidy. Telomerase activity is also a hallmark of most cancers, which reactivate it precisely to escape the replicative limit that telomere shortening imposes. A compound proposed to raise telomerase activity systemically is proposing to alter a mechanism that works in both directions.

Whether epithalon does this in humans at all is unestablished; the telomerase findings are in cell culture. The point is not that the compound is dangerous — there is no human evidence either way — but that the mechanism is not self-evidently beneficial, and articles that present telomerase activation as an unmixed good are skipping the part that would make it worth discussing with a clinician.

The pulse schedule, and what is not known

The dosing pattern the app records is distinctive: a short course of daily administration — ten to twenty days — repeated once or twice a year, rather than continuous use. That pattern comes from the original research protocols rather than from pharmacokinetic reasoning, and the app holds no half-life or time-to-peak for this compound, which is why the fact box above has no pharmacokinetic rows. Nobody has published the characterisation those rows would come from.

There is no approved product outside the jurisdiction where the underlying research was done, no controlled Western trial, and no established human dose. Identity and purity rest with whoever produced the vial, as with every research compound, and this site names no vendor or testing service. The peptide ships lyophilised and becomes a refrigerated, time-limited solution once reconstituted; the storage rule above is the app's own.

The honest position is that this is a compound with an interesting and genuinely published research programme behind it, concentrated in a way that makes independent replication the thing to wait for, and with a mechanism whose desirability is not obvious. Anyone using it or considering it should raise it with a clinician who knows their history, including their cancer screening history.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Epithalon, verbatim. None of the analytes it names has a page here yet.

Drawbacks and risks the app records

From the app's own entry, and unusually candid — the first three items describe the state of the evidence rather than an adverse effect, which is the correct emphasis here.

• Most research from one research group (Khavinson)
• Needs independent replication
• Very limited long-term human data
• Mechanism translation to humans uncertain
• Not FDA approved
• Limited Western peer-reviewed data
• Primarily Russian research base
• Long-term effects in healthy subjects not fully established
• Requires injection or intranasal administration

Questions people actually ask

Is there any Western trial evidence?

No controlled Western trial has been published. The research base is the Russian gerontology programme described above, and independent replication of its central findings is what is missing rather than contradicted.

Why is the dosing a short course twice a year?

Because that is the pattern used in the original research protocols. It is not derived from pharmacokinetics — the app holds no half-life for this compound, because none has been published — so the interval reflects a research convention rather than a measured property.

Does it lengthen telomeres in people?

That has not been demonstrated in humans. The telomerase and telomere findings are in cell culture. Whether the same thing happens in a person given a short course of the peptide is unknown, and it would not automatically be desirable if it did.

How does it relate to melatonin?

The original preparation was derived from pineal tissue, and one of the reported effects is normalisation of melatonin rhythm — which is the basis for the sleep and circadian claims attached to it. That link is from the same research lineage as everything else here.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.